Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy

Outcomes remain poor for patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (R/R B‐NHL). While chimeric antigen receptor (CAR) T‐cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock, Matt, Elavalakanar, Pavania, Bright, Susan, Ambati, Srikanth R., Brouwer‐Visser, Jurriaan, Pourpe, Stephane, Fiaschi, Nathalie, Jankovic, Vladimir, Thurston, Gavin, Deering, Raquel P., Chaudhry, Aafia, Joyce, Robin, Arnason, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796753/
https://www.ncbi.nlm.nih.gov/pubmed/35892294
http://dx.doi.org/10.1111/bjh.18383
_version_ 1784860558297661440
author Weinstock, Matt
Elavalakanar, Pavania
Bright, Susan
Ambati, Srikanth R.
Brouwer‐Visser, Jurriaan
Pourpe, Stephane
Fiaschi, Nathalie
Jankovic, Vladimir
Thurston, Gavin
Deering, Raquel P.
Chaudhry, Aafia
Joyce, Robin
Arnason, Jon
author_facet Weinstock, Matt
Elavalakanar, Pavania
Bright, Susan
Ambati, Srikanth R.
Brouwer‐Visser, Jurriaan
Pourpe, Stephane
Fiaschi, Nathalie
Jankovic, Vladimir
Thurston, Gavin
Deering, Raquel P.
Chaudhry, Aafia
Joyce, Robin
Arnason, Jon
author_sort Weinstock, Matt
collection PubMed
description Outcomes remain poor for patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (R/R B‐NHL). While chimeric antigen receptor (CAR) T‐cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B‐NHL in a first‐in‐human trial (NCT02290951). Here, we document two patients with diffuse large B‐cell lymphoma refractory to CART‐cell therapy. Both achieved complete responses that remain ongoing for ≥2 years following odronextamab. Neither patient experienced Grade ≥3 cytokine release syndrome or Grade ≥3 neurological adverse events during treatment.
format Online
Article
Text
id pubmed-9796753
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97967532023-01-04 Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy Weinstock, Matt Elavalakanar, Pavania Bright, Susan Ambati, Srikanth R. Brouwer‐Visser, Jurriaan Pourpe, Stephane Fiaschi, Nathalie Jankovic, Vladimir Thurston, Gavin Deering, Raquel P. Chaudhry, Aafia Joyce, Robin Arnason, Jon Br J Haematol Haematological Malignancy–Clinical Outcomes remain poor for patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (R/R B‐NHL). While chimeric antigen receptor (CAR) T‐cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B‐NHL in a first‐in‐human trial (NCT02290951). Here, we document two patients with diffuse large B‐cell lymphoma refractory to CART‐cell therapy. Both achieved complete responses that remain ongoing for ≥2 years following odronextamab. Neither patient experienced Grade ≥3 cytokine release syndrome or Grade ≥3 neurological adverse events during treatment. John Wiley and Sons Inc. 2022-07-27 2022-11 /pmc/articles/PMC9796753/ /pubmed/35892294 http://dx.doi.org/10.1111/bjh.18383 Text en © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Haematological Malignancy–Clinical
Weinstock, Matt
Elavalakanar, Pavania
Bright, Susan
Ambati, Srikanth R.
Brouwer‐Visser, Jurriaan
Pourpe, Stephane
Fiaschi, Nathalie
Jankovic, Vladimir
Thurston, Gavin
Deering, Raquel P.
Chaudhry, Aafia
Joyce, Robin
Arnason, Jon
Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
title Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
title_full Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
title_fullStr Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
title_full_unstemmed Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
title_short Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
title_sort complete responses to odronextamab in two patients with diffuse large b‐cell lymphoma refractory to chimeric antigen receptor t‐cell therapy
topic Haematological Malignancy–Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796753/
https://www.ncbi.nlm.nih.gov/pubmed/35892294
http://dx.doi.org/10.1111/bjh.18383
work_keys_str_mv AT weinstockmatt completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT elavalakanarpavania completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT brightsusan completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT ambatisrikanthr completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT brouwervisserjurriaan completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT pourpestephane completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT fiaschinathalie completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT jankovicvladimir completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT thurstongavin completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT deeringraquelp completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT chaudhryaafia completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT joycerobin completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy
AT arnasonjon completeresponsestoodronextamabintwopatientswithdiffuselargebcelllymphomarefractorytochimericantigenreceptortcelltherapy

Ejemplares similares